Health Economics›Glioblastoma›Maintenance after first-line therapy

Maintenance after first-line therapy

Glioblastoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Irinotecan and Bevacizumab Variant #01	—	R 19 884	14d	—	—	—	—	—
Temozolomide monotherapy Variant #13	—	R 8 153	28d	4.0 mo	18.8 mo	5	R 40 764 PFS proxy	5
Temozolomide and TTFields Variant #01	—	R 8 153	28d	7.1 mo	20.9 mo	8	R 65 223 PFS proxy	2

3 of 3 regimens shown